AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2019
Jan 3, 2019
30591_dirs_2019-01-03_f30a78f2-f7bf-4945-b13f-2c5f8b7b2737.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IONIS PHARMACEUTICALS INC (IONS)
CIK: 0000874015
Period of Report: 2019-01-01
Reporting Person: HOUGEN ELIZABETH L (SVP Finance & CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-01-01 | Common Stock | J | 127 | $36.448 | Acquired | 14901 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-02 | Employee Stock Option (right to buy) | $53.77 | A | 49800 | Acquired | 2026-01-01 | Common Stock (49800) | Direct |
Footnotes
F1: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019.
F2: Grant of 01/02/2019 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019.